Explore practical health tips, the latest medical news, and expert wellness advice to help you maintain a balanced and healthy lifestyle every day.
(MedPage Today) — SAN FRANCISCO — Adjuvant durvalumab (Imfinzi) and tremelimumab (Imjudo) improved disease-free survival (DFS) in a phase III trial of resectable renal cell carcinoma (RCC), but researchers here...
(MedPage Today) — Understaffing of hospital nurses was linked to worse patient outcomes, especially during day shifts, according to a retrospective cohort study from Japan. Among more than 77,000 hospital...
(MedPage Today) — HHS Secretary Robert F. Kennedy Jr. said that he has attention deficit-hyperactivity disorder (ADHD) during an appearance on Joe Rogan’s podcast that aired on Friday. The two...
(MedPage Today) — SAN FRANCISCO — Despite a growing emphasis on quality-of-life (QoL) endpoints and patient-reported outcomes in cancer trials, the reporting of those results has been inconsistent for prostate,...
(MedPage Today) — In “Beyond Diagnosis: Alzheimer’s Disease,” Cleveland Clinic behavioral neurologist Jagan Pillai, MD, PhD, and host Glenn Campbell discuss how to communicate effectively with patients and families about...
(MedPage Today) — PHILADELPHIA — Most multi-food allergic children succeeded in longer term regular dietary consumption whether treated with oral immunotherapy (OIT) or omalizumab (Xolair) alone, results from stage 3...
(MedPage Today) — “The situation is alarming.” — Robert Lawrence, MD, of Johns Hopkins University in Baltimore, warning that HHS could eliminate or delegitimize the U.S. Preventive Services Task Force...
(MedPage Today) — Chronic migraine patients who used GLP-1 receptor agonists to treat conditions like obesity or diabetes had fewer emergency department (ED) visits than those on topiramate (Topamax), a...
(MedPage Today) — DENVER — An estimated one in 12 U.S. adolescents with early syphilis also have HIV in a national surveillance sample, but the burden of co-occurring syphilis and...
(MedPage Today) — PHILADELPHIA — For multi-allergen oral immunotherapy (mOIT) patients, adding dupilumab (Dupixent) after omalizumab (Xolair) showed promise for cutting the gastrointestinal adverse events (AE) of ongoing mOIT, although...
